论文部分内容阅读
目的观察依达拉奉联合丁苯酞治疗急性脑梗死的临床疗效。方法选取200例在宝鸡市人民医院就诊的急性脑梗死患者,随机分为观察组100例,给予依达拉奉注射液联合丁苯酞治疗,对照组100例,仅给予丁苯酞治疗。对两组患者的临床疗效、NDS评分、Mo CA评分、ADL评分及血清C-反应蛋白(hs-CRP)水平及不良反应进行比较。结果观察组总有效率(92%)显著高于对照组(79%),差异具有统计学意义(P<0.05)。治疗后两组患者神经功能缺损均有所下降,认知功能均有所改善,但观察组神经功能缺损下降显著低于对照组,认知功能改善优于对照组,观察组ADL评分显著高于对照组,hs-CRP水平显著低于对照组,差异具有统计学意义(P<0.05)。所有患者治疗过程中无明显不良反应。结论依达拉奉注射液联合丁苯酞对急性脑梗死疗效显著,安全性好,值得临床推广。
Objective To observe the clinical efficacy of edaravone and butylphthalide in the treatment of acute cerebral infarction. Methods A total of 200 patients with acute cerebral infarction who were treated in Baoji People’s Hospital were randomly divided into observation group (100 cases), edaravone injection combined with butylphthalide (100 cases) and butylphthalide treatment group (100 cases). The clinical efficacy, NDS score, MoCA score, ADL score and serum C-reactive protein (hs-CRP) levels and adverse reactions in both groups were compared. Results The total effective rate (92%) in the observation group was significantly higher than that in the control group (79%), the difference was statistically significant (P <0.05). After treatment, the neurological deficit in both groups decreased and the cognitive function improved. However, the decline of neurological deficit in observation group was significantly lower than that of control group, and the improvement of cognitive function was superior to that of control group. ADL score of observation group was significantly higher than that of control group The level of hs-CRP in the control group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). All patients treated with no significant adverse reactions. Conclusion Edaravone injection combined with butylphthalide has significant curative effect on acute cerebral infarction and its safety is good. It is worthy of clinical promotion.